Breaking News: Elon Musk Invents New Type of A.I. (Shocking)

Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street veteran, Eric Fry… This mind-blowing new technology could be bigger than the iPhone.

Timothy J. Scannell net worth and biography

Timothy Scannell Biography and Net Worth

Director of Insulet

Mr. Scannell has served on our Board of Directors since August 2014 and as our Board Chair since January 1, 2019. He also serves on the Board of Directors of Novocure, Renalytix and AeroClean Technologies. From October 2021 to March 2023, he served as an Executive Advisor at Stryker Corporation, one of the world's leading medical technology companies that offers innovative products and services in Orthopaedics, Medical and Surgical, and Neurotechnology and Spine that help improve patient and hospital outcomes. From August 2018 to September 2021, he served as the President and Chief Operating Officer at Stryker, and from 2009 to August 2018, he served as a Group President and oversaw Stryker’s MedSurg and Neurotechnology divisions. From 1990 to 2009, Mr. Scannell served in various roles at Stryker, including a range of sales and marketing leadership roles, Vice President and General Manager of its Biotech division and President of its Spine business. Mr. Scannell holds a Bachelor of Business Administration and a Master of Business Administration from the University of Notre Dame. He brings extensive strategic, organizational, and operational skills and experience.

What is Timothy J. Scannell's net worth?: The estimated net worth of Timothy J. Scannell is at least $7.00 million as of June 10th, 2024. Mr. Scannell owns 35,586 shares of Insulet stock worth more than $7,000,478 as of July 4th. This net worth approximation does not reflect any other investments that Mr. Scannell may own. Learn More about Timothy J. Scannell's net worth.
How do I contact Timothy J. Scannell?: The corporate mailing address for Mr. Scannell and other Insulet executives is 100 NAGOG PARK, ACTON MA, 01720. Insulet can also be reached via phone at (978) 600-7000 and via email at [email protected]. Learn More on Timothy J. Scannell's contact information.
Has Timothy J. Scannell been buying or selling shares of Insulet?: Timothy J. Scannell has not been actively trading shares of Insulet during the last quarter. Most recently, Timothy J. Scannell sold 7,000 shares of the business's stock in a transaction on Monday, June 10th. The shares were sold at an average price of $190.51, for a transaction totalling $1,333,570.00. Following the completion of the sale, the director now directly owns 35,586 shares of the company's stock, valued at $6,779,488.86. Learn More on Timothy J. Scannell's trading history.
Who are Insulet's active insiders?: Insulet's insider roster includes Charles Alpuche (COO), Eric Benjamin (SVP), Luciana Borio (Director), Bret Christensen (EVP), Sally Crawford (Director), John Fallon (Director), Mark Field (SVP and Chief Technology Officer), James Hollingshead (CEO), Dan Manea (SVP), Wayde McMillan (CFO), Shacey Petrovic (CEO), Timothy Scannell (Director), Prem Singh (SVP), and Michael Spears (SVP). Learn More on Insulet's active insiders.
Are insiders buying or selling shares of Insulet?: In the last twelve months, Insulet insiders bought shares 2 times. They purchased a total of 5,551 shares worth more than $1,006,994.42. In the last twelve months, insiders at the medical instruments supplier sold shares 6 times. They sold a total of 45,540 shares worth more than $7,814,224.61. The most recent insider tranaction occured on June, 14th when SVP Mark N Field sold 1,500 shares worth more than $299,940.00. Insiders at Insulet own 0.5% of the company. Learn More about insider trades at Insulet.
Information on this page was last updated on 6/14/2024.

Timothy J. Scannell Insider Trading History at Insulet

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/10/2024	Sell	7,000	$190.51	$1,333,570.00	35,586
5/28/2024	Sell	3,300	$180.90	$596,970.00	42,586
5/15/2015	Buy	3,500	$27.05	$94,675.00

Timothy J. Scannell Buying and Selling Activity at Insulet

Insulet Company Overview

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Today's Range

Now: $196.72

$194.49

$199.34

50 Day Range

MA: $185.42

$161.02

$206.98

2 Week Range

Now: $196.72

$125.82

$293.64

Volume

266,689 shs

Average Volume

870,052 shs

Market Capitalization

$13.78 billion

P/E Ratio

59.61

Dividend Yield

N/A

Beta

1.16

DOLLAR RECALL ON THE AGENDA

From Golden Crest | Ad

Have you heard about Executive Order 14067? This lesser-known order introduced the Digital Dollar, an alarming plan aimed at controlling your spending. And it gets even more concerning: in November, the Federal Government and banks initiated a test program to implement the Digital Dollar.

Click here to receive your complimentary Wealth Management Guide >>